Document resource
Background and Importance Pharmaceutical Interventions (PI) reduce medication errors and improve the safe use of antineoplastic agents. However, the lack of standardised documentation limits impact assessment. In our country, the limited published evidence highlights the need for structured recording systems to ensure visibility and measurability of these contributions.Aim and Objectives To implement a standardised tool for documenting Drug-Related Problems (DRP) and associated PI within a Cytotoxic Production Unit (CPU), and to evaluate DRP types, PI characteristics, and acceptance rates.Material and Methods A single-centre, prospective observational pilot study was conducted in the CPU, focusing on antineoplastic preparations for adult oncology patients (≥18 years). A Microsoft Forms questionnaire, based on The PCNE Classification V 9.1, was developed to record DRP and PI. Three trained pharmacists used the tool during routine operations from 1 February to 31 August 2025. Prescription validation data were extracted from the Integrated Medication Circuit Management System (SGICM) and cross-checked with free-text notes. Descriptive analysis was performed using Microsoft Excel.Results Of 8,157 prescription validations, 257 DRP were identified: 51.0% adverse drug reactions and 35.8% suboptimal effects. 79.8% were resolved; 4.3% remained unresolved, mainly due to prescriber interface issues. Leading causes included inappropriate drug prescribed according to guidelines/formulary (17.5%) and low dosage (13.6%). 315 PI were performed: 84.8% at healthcare professional level (78.3% physicians; 15.7% nurses; 5.2% pharmacists; 0.7% technicians); 2.5% at patient level; 12.7% other. Of 212 medication-change PI, dose adjustment (41.5%) and drug discontinuation/interruption (25.5%) were most frequent. Among 180 proposals to physicians, 93.9% were accepted.Conclusion and Relevance The implemented tool enabled consistent, quantifiable DRP/PI documentation in the CPU. High acceptance and DRP resolution rates suggest clinical benefits. However, downstream outcomes weren’t assessed and only a small share of validations had recorded DRP/PI, so unit-wide impact is unclear. The low rate may reflect missed entries at peak times, narrow antineoplastics focus or already optimised prescribing. Limitations include single-centre design, short study duration, and limited user base. Future steps involve expanding tool usage across the team, integrating feedback for refinement, set local improvement targets and embedding PI documentation into patient clinical records to enhance continuity of care.Conflict of Interest No conflict of interest